Alumis Inc. $ALMS Stake Boosted by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA increased its stake in Alumis Inc. (NASDAQ:ALMS) by 6,070.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 647,366 shares of the company’s stock after buying an additional 636,875 shares during the period. Pictet Asset Management Holding SA owned 0.50% of Alumis worth $4,784,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. BlackRock Inc. bought a new stake in Alumis during the 2nd quarter valued at approximately $231,259,000. venBio Partners LLC bought a new position in shares of Alumis in the 2nd quarter worth approximately $127,429,401. Jupiter Topco LLC bought a new position in shares of Alumis in the 2nd quarter worth approximately $66,238,000. Octagon Capital Advisors LP raised its position in shares of Alumis by 11.9% in the 1st quarter. Octagon Capital Advisors LP now owns 2,830,700 shares of the company’s stock worth $62,360,000 after acquiring an additional 300,000 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of Alumis in the 1st quarter worth approximately $46,790,000.

Wall Street Analyst Weigh In

ALMS has been the topic of several research reports. Benchmark restated a “buy” rating on shares of Alumis in a research report on Monday, October 5th. Wall Street Zen cut Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th. Morgan Stanley decreased their price objective on Alumis from $39.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, September 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Wednesday, September 16th. Finally, HC Wainwright lowered their price objective on Alumis from $15.00 to $9.00 and set a “buy” rating for the company in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.09.

Latest Alumis News

Here’s some of the latest news about ALMS:

• Positive Sentiment: Alumis reported new Phase 3 data showing rapid, durable improvements in plaque psoriasis. The company said envudeucitinib had the highest publicly reported Week 48 PASI 100 response rate among existing and investigational oral psoriasis therapies, reinforcing its potential clinical differentiation. Alumis Q3 2026 financial results and business updates
• Neutral Sentiment: Q3 adjusted performance was slightly better than expected: the loss was $0.73 per share versus the $0.76 consensus, while revenue of $1.91 million was essentially in line with estimates of $1.90 million. The small beat is tempered by continued losses. Alumis earnings results
• Negative Sentiment: Wells Fargo cut its price target to $18 from $25, and HC Wainwright lowered its target to $9 from $15. Both firms kept bullish ratings—Overweight and Buy, respectively—but the reductions may signal more cautious expectations and pressure the stock. Wells Fargo price target report

Insider Buying and Selling

In other Alumis news, Director Srinivas Akkaraju sold 96,131 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $10.55, for a total value of $1,014,182.05. Following the sale, the director directly owned 2,025,493 shares of the company’s stock, valued at approximately $21,368,951.15. The trade was a 4.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 99,754 shares of company stock valued at $1,037,804 over the last 90 days. Insiders own 33.70% of the company’s stock.

Alumis Stock Down 8.6%

Shares of NASDAQ ALMS traded down $0.53 on Friday, reaching $5.60. 1,492,040 shares of the company’s stock traded hands, compared to its average volume of 1,844,219. The business’s 50 day simple moving average is $7.24 and its two-hundred day simple moving average is $20.46. Alumis Inc. has a 12 month low of $4.60 and a 12 month high of $31.35. The company has a market cap of $724.81 million, a price-to-earnings ratio of -1.59 and a beta of -0.28.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.03. Alumis had a negative return on equity of 86.62% and a negative net margin of 5,844.54%. The firm had revenue of $1.91 million for the quarter, compared to analysts’ expectations of $1.90 million. Analysts forecast that Alumis Inc. will post -2.95 earnings per share for the current fiscal year.

Alumis Company Profile

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.